All In Biotech

Drug Trial Radar · NCT07803965

Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy

A Randomized, Placebo-Controlled Phase IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and Preliminary Efficacy of SGC001 Injection in Participants With Predicted Severe Acute Pancreatitis.

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

129

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Nov 2027

Study completion Jan 2028

Sponsor

Sponsor type
Industry
First posted
Sep 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an early phase clinical study. Patients who are at high risk of developing severe acute pancreatitis will be screened. Participants will be randomly assigned to receive either SGC001 injection or a placebo injection that contains no active medicine. The study will check how safe and well tolerated SGC001 is, how the body processes this study drug, its biological effects, and whether it may help treat this condition. The study consists of Part A, a dose escalation phase primarily focused on safety and tolerability, and Part B, a dose exploration phase primarily focused on efficacy, both administered as a single add on dose to standard care in patients with predicted severe acute pancreatitis.

Conditions

  • Acute Pancreatitis

Interventions

  • SGC001 injectionDrug

    Specification:400mg (10mL) per vial Part A: Dosage and Administration:300mg or 600mg, other dosage determined by the safety review committee (SRC) administered as a single intravenous infusion Infusion Duration:60±10minutes Part B: Based on clinical pharmacokinetic, safety and/or efficacy data obtained from the Part A dose escalation phase, the SRC will select 1 or 2 optimal dose cohorts. Infusion Duration:60±10minutes administered as a single intravenous infusion

  • PlaceboDrug

    Specification: 0mg(10mL)per vial Dosage Administration: 0mg as a single intravenous infusion Infusion Duration:60±10minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety Adverse Event (AE)Time frame: Part A Safety: Day 0- Day 85
  2. Part B: Days alive free of organ failure within 14 days post-randomizationTime frame: Part B: Day 1-Day 15

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • West China Hospital, Sichuan University

    Chengdu, China · Not yet recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guizhou, China · Not yet recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, China · Not yet recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Not yet recruiting

  • General Hospital of the Eastern Theater Command of the Chinese People's Liberation Army

    Nanjing, China · Recruiting

  • Li Huili Hospital, Ningbo Medical Center

    Ningbo, China · Not yet recruiting

  • Shanghai General Hospital

    Shanghai, China · Not yet recruiting

  • General Hospital of Northern Theater Command of the Chinese People's Liberation Army

    Shenyang, China · Not yet recruiting

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, China · Not yet recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, China · Not yet recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China · Not yet recruiting

  • Zhongshan Hospital, Xiamen University

    Xiamen, China · Not yet recruiting

  • Zibo Central Hospital

    Zibo, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.